Collaboration and Option Agreement Sample Contracts

ARTICLE 1 DEFINITIONS
Collaboration and Option Agreement • April 15th, 2005 • Mymetics Corp • Biological products, (no disgnostic substances)
AutoNDA by SimpleDocs
EX-10.46 3 dex1046.htm COLLABORATION AND OPTION AGREEMENT Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisk denote omissions. COLLABORATION AND OPTION AGREEMENT by and between Infinity...
Collaboration and Option Agreement • May 5th, 2020 • Delaware

This Agreement is made this 16th day of November, 2004 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc. (“Infinity”), a Delaware corporation with principal offices at 780 Memorial Drive, Cambridge, Massachusetts 02139, and Novartis International Pharmaceutical Ltd. (“Novartis”), a Bermuda corporation with principal offices at Hurst Holme, 12 Trott Road, Hamilton, HM LX, Bermuda. Infinity and Novartis are sometimes referred to herein individually as a “Party” and together as the “Parties.”

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Collaboration and Option Agreement Between MORPHIC...
Collaboration and Option Agreement • June 24th, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • New York

This Collaboration and Option Agreement (this “Agreement”) is made and entered into as of October 16, 2018, 2018 (the “Execution Date”) by and between Morphic Therapeutic, Inc., a Delaware corporation (“Morphic”) and AbbVie Biotechnology Ltd, a corporation organized under the laws of Bermuda having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”). Morphic and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Contract
Collaboration and Option Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations • New York

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Contract
Collaboration and Option Agreement • June 16th, 2014 • Globeimmune Inc • Pharmaceutical preparations • New York

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

EX-10.11 16 a2236234zex-10_11.htm EX-10.11 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting...
Collaboration and Option Agreement • May 5th, 2020 • England and Wales

This COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is made effective as of the “Effective Date” by and between ARIDIS PHARMACEUTICALS LLC, a company organized and existing under the laws of California having its registered office at 5941 Optical Court, San Jose, CA, 95138 USA (“ARIDIS”), and GLAXOSMITHKLINE BIOLOGICALS S.A., a company organized and existing under the laws of Belgium under number RPM Nivelles — BE — 0440 872918 and having its registered office at rue de l’Institut 89, 1330 Rixensart, Belgium (“GSK”). ARIDIS and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • California

THIS COLLABORATION AND OPTION AGREEMENT (“Agreement”) dated as of December 22, 2010 (“Effective Date”), is entered into between XENCOR, INC., a Delaware corporation having its principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”) and AMGEN INC., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”). Amgen and Xencor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the definitions set forth in Article 1.

EX-10.2(B) 3 d344523dex102b.htm AMENDMENT 1 TO THE COLLABORATION AND OPTION AGREEMENT [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been...
Collaboration and Option Agreement • May 5th, 2020

THIS AMENDMENT 1 TO THE COLLABORATION AND OPTION AGREEMENT (the “Amendment”) is made and entered into on August 1st, 2012 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

COLLABORATION AND OPTION AGREEMENT BY AND BETWEEN ONCOMED PHARMACEUTICALS, INC. AND BAYER SCHERING PHARMA AG DATED JUNE 15, 2010
Collaboration and Option Agreement • July 5th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York

THIS COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is made and entered into as of June 15, 2010 (the “Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Schering Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Amendment # 2 to the Collaboration and Option Agreement
Collaboration and Option Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations

This is a Second Amendment (“Amendment #2”) to the Collaboration and Option Agreement dated May 14th 2009 (the “Agreement) by and between Celgene Corporation, a Delaware Corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“Celgene”), and GlobeImmune, Inc., a Delaware Corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (“GlobeImmune”).

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...
Collaboration and Option Agreement • June 4th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales

THIS COLLABORATION AND OPTION AGREEMENT is entered into and made effective as of the 10th day of April, 2018 (the “Effective Date”), by and among:

AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • August 16th, 2012 • Globeimmune Inc • Pharmaceutical preparations

THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this “Amendment #3”) is made and entered into as of June 16, 2011 (the “Amendment #3 Effective Date”), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (“GlobeImmune”), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (“Celgene”). GlobeImmune and Celgene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Amendment # 1 to the Collaboration and Option Agreement
Collaboration and Option Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations

This is an Amendment (“Amendment”) to the Collaboration and Option Agreement dated May 14th 2009 (the “Agreement) by and between Celgene Corporation, a Delaware corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“Celgene”), and GlobeImmune, Inc., a Delaware corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (“GlobeImmune”).

COLLABORATION AND OPTION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND ABBVIE IRELAND UNLIMITED COMPANY February 21, 2019
Collaboration and Option Agreement • February 26th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

Each Regulatory Milestone Payment set forth in Section 10.2.2(a) is payable only once for each Licensed Compound (e.g., if a [**]). Only one Regulatory Milestone Payment is payable for each Milestone Event for a Licensed Compound, even if multiple Licensed Products that contain or are comprised of such Licensed Compound achieve such Milestone Event. Only one Milestone Payment is payable for each Milestone Event for a Licensed Product, irrespective of the number of Licensed Compounds contained by such Licensed Product. By way of example and not limitation, if a Licensed Product containing or comprised of Licensed Compound x achieves the Milestone Event in Section 10.2.2(a)(ii), then no additional Milestone Payment shall be due if a different Licensed Product containing or comprised of Licensed Compound x achieves such Milestone Event.

AMENDMENT NO. 5 TO COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • March 11th, 2011 • Cytokinetics Inc • Pharmaceutical preparations

This Amendment No. 5 to the Agreement (this “Amendment No. 5”) is entered into as of November 1, 2010 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).

AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations

THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this “Amendment #3”) is made and entered into as of June 16, 2011 (the “Amendment #3 Effective Date”), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (“GlobeImmune”), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (“Celgene”). GlobeImmune and Celgene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

AMENDMENT 2 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • November 13th, 2013 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations

THIS AMENDMENT 2 TO THE COLLABORATION AND OPTION AGREEMENT (the “Amendment”) is made and entered into on August 27, 2013 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc. a Delaware corporation located at 800 Chesapeake Drive. Redwood City, California 94063. United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Amendment No. 1 to Pilot Collaboration and Option Agreement
Collaboration and Option Agreement • November 9th, 2023 • Synlogic, Inc. • Pharmaceutical preparations

This amendment no. 1 to the Pilot Collaboration and Option Agreement effective as of 16 June 2021 (the "Amendment No. 1") is entered into effective as of 15 August, 2023 (the "Amendment No. 1 Effective Date") by and between Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. ("Roche US") and F. Hoffmann-La Roche Ltd, located at Grenzacherstrasse 124, 4070 Basel, Switzerland ("Roche Basel", Roche Basel and Roche US together referred to as “Roche”), on the one hand, and Synlogic Operating Company, Inc., located at 301 Binney St., Suite 402, Cambridge, MA 02142 (hereafter referred to as “Synlogic”), on the other hand.

AMENDMENT 6 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • August 2nd, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations

This Amendment 6 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on June 13, 2018 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany (“Bayer”). OncoMed and Bayer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

AMENDMENT 4 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • November 1st, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations

This Amendment 4 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

COLLABORATION AND OPTION AGREEMENT BY AND BETWEEN FATE THERAPEUTICS, INC. AND JANSSEN BIOTECH, INC. DATED APRIL 2, 2020
Collaboration and Option Agreement • August 5th, 2020 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • New York

This Collaboration and Option Agreement (the “Agreement”) is made and entered into as of April 2, 2020 (the “Effective Date”), by and between Fate Therapeutics, Inc., a Delaware corporation located at 3535 General Atomics Court, Suite 200, San Diego, California 92121, United States of America (“Fate”), and Janssen Biotech, Inc., a Pennsylvania corporation located at 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044, United States of America (“Janssen”). Fate and Janssen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION Amendment #1 to the Collaboration and Option Agreement dated May 17, 2010 By and between Fluidigm Corporation and Novartis Vaccines and Diagnostics, Inc.
Collaboration and Option Agreement • April 4th, 2011 • Fluidigm Corp • Laboratory analytical instruments

Incorporating the terms and conditions of the Collaboration and Option Agreement made effective May 17, 2010 (hereinafter referred to as the “Agreement”), made by and between Novartis Vaccines and Diagnostics, Inc. (“Novartis”) and Fluidigm Corporation (“Fluidigm”), the Agreement is amended, effective as of March 15, 2011.

AutoNDA by SimpleDocs
Amendment #1 to Research collaboration and option agreement
Collaboration and Option Agreement • November 25th, 2019 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations

This Amendment (hereinafter “Amendment #1”), is made, and effective, as of the date of execution by the last Party to sign below (the “Execution Date”), is to the Research Collaboration and Option Agreement having an Execution Date of October 3, 2018 (the “Agreement”), by and between Arrowhead Pharmaceuticals, Inc., a Delaware corporation with a place of business at 225 South Lake Avenue, Suite 1050, Pasadena, California 91101, USA (“Arrowhead”), and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation with a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (“Janssen”).

AMENDMENT TO COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • May 26th, 2005 • Myogen Inc • Pharmaceutical preparations

This Amendment to Collaboration and Option Agreement (“Amendment”) is entered into as of May 23, 2005 (the “Amendment Date”) by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 W. 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.

Annex 1: Heads of Terms Collaboration and Option Agreement
Collaboration and Option Agreement • August 22nd, 2024 • England

This proposed transaction is subject to (i) the acceptance by both Parties of the principal terms as finally negotiated, and (ii) the negotiation, execution and delivery of a definitive Agreement. This Term Sheet does not constitute a binding contract, and the Parties do not intend to be legally bound, unless and until a definitive Agreement has been executed by both Parties. Unless and until a definitive Agreement has been executed by both Parties, either Party is free to terminate further negotiations at any time, with or without cause.

AMENDMENT 5 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • March 9th, 2017 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations

This Amendment 5 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into as of December 15, 2016 (the “Amendment Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...
Collaboration and Option Agreement • February 14th, 2022 • Dynamics Special Purpose Corp. • Blank checks • Massachusetts

This COLLABORATION AND OPTION AGREEMENT (the “Agreement”), effective as of May 21, 2021 (the “Effective Date”), is made by and between SENTI BIOSCIENCES, INC., a Delaware corporation with its principal place of business at 2 Corporate Drive, South San Francisco, CA 94080 (“Senti”), and the BLUEROCK THERAPEUTICS LP, a Delaware limited partnership with its principal place of business at One Broadway, Floor Fifteen, Cambridge, MA 02142 (“BlueRock”). Senti and BlueRock are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

EX-10.16 24 a2235907zex-10_16.htm EX-10.16
Collaboration and Option Agreement • May 5th, 2020

Confidential treatment has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • March 21st, 2024 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances)

This Collaboration and Option Agreement (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of November 6, 2023 (the “Effective Date”), by and between Senti Biosciences, Inc., a Delaware corporation with its principal place of business at 2 Corporate Drive, South San Francisco, CA 94080 (“Senti”), and Celest Therapeutics (Shanghai) Co. Ltd, a limited company organized under the laws of the People’s Republic of China, with its principal place of business at 3rd Floor, Building No. 1, 795 Kangwei Rd, Pudong, Shanghai, China, 201315 and uniform social credit code of 91310115MA1K4QQK97 (“Celest”). Senti and Celest are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

Collaboration and Option Agreement"
Collaboration and Option Agreement • January 25th, 2023
AMENDMENT 3 TO THE COLLABORATION AND OPTION AGREEMENT
Collaboration and Option Agreement • March 10th, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations

This Amendment 3 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on November 4, 2015 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Dealdoc‌
Collaboration and Option Agreement • January 29th, 2022 • California

Collaborative R&D, licensing and option agreement for XmAb5871 monoclonal antibodies for autoimmune diseases (terminated)

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND OPTION AGREEMENT dated as of August 12,...
Collaboration and Option Agreement • December 18th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • New York

This COLLABORATION AND OPTION AGREEMENT (as may be amended in accordance with its terms, the “Agreement”), dated as of August 12, 2022 (the “Effective Date”), is made by and between Q32 BIO INC., a Delaware corporation (the “Company”), and HORIZON THERAPEUTICS IRELAND DAC, a company organized under the laws of Ireland (“Horizon”). Each of the Company and Horizon is referred to herein, individually, as a “Party” and, collectively, as the “Parties.”

Collaboration and Option Agreement between Amgen Inc. and Cytokinetics, Incorporated dated December 29, 2006
Collaboration and Option Agreement • March 12th, 2007 • Cytokinetics Inc • Pharmaceutical preparations • California

This Collaboration and Option Agreement (this “Agreement”) is entered into as of the 29th day of December, 2006 (the “Effective Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (“CK”) and Amgen Inc., a Delaware corporation (“Amgen”). CK and Amgen are sometimes referred to herein, individually, as a “Party” or, collectively, as “Parties.”

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!